{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:24:51Z","timestamp":1791289491460,"version":"4.3.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0848-y","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T07:03:48Z","timestamp":1519715028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-2277","authenticated-orcid":false,"given":"Ryo","family":"Koda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"848_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160\u20139.","journal-title":"Am J Nephrol"},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017;32:936\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"848_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638\u201347.","journal-title":"Kidney Int"},{"key":"848_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68:287\u201391.","journal-title":"Am J Kidney Dis"},{"key":"848_CR7","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1681\/ASN.2006050418","volume":"17","author":"Z Spanou","year":"2006","unstructured":"Spanou Z, Keller M, Britschgi M, et al. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006;17:2919\u201327.","journal-title":"J Am Soc Nephrol"},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1378\/chest.07-3088","volume":"134","author":"Y Suzuki","year":"2008","unstructured":"Suzuki Y, Miwa S, Shirai M, et al. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Chest. 2008;134:1027\u201332.","journal-title":"Chest"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141\u201351.","journal-title":"Immunity"},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.2621","volume":"18","author":"VK Kuchroo","year":"2012","unstructured":"Kuchroo VK, Ohashi PS, Sartor RB, et al. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med. 2012;18:42\u20137.","journal-title":"Nat Med"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"848_CR12","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/ndt\/gfh423","volume":"19","author":"R Schoop","year":"2004","unstructured":"Schoop R, Wahl P, Le Hir M, et al. Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant. 2004;19:2713\u201320.","journal-title":"Nephrol Dial Transplant"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, et al. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9:411\u20137.","journal-title":"Clin Kidney J"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"M-L Blank","year":"2014","unstructured":"Blank M-L, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86:837\u201344.","journal-title":"Kidney Int"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","volume":"64","author":"AK Muriithi","year":"2014","unstructured":"Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis. 2014;64:558\u201366.","journal-title":"Am J Kidney Dis"},{"key":"848_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u201346.","journal-title":"JAMA Intern Med"},{"key":"848_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.ackd.2016.11.004","volume":"24","author":"R Raghavan","year":"2017","unstructured":"Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24:64\u201371.","journal-title":"Adv Chronic Kidney Dis"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361:211\u20132.","journal-title":"N Engl J Med"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1440-1797.2006.00651.x","volume":"11","author":"IJ Simpson","year":"2006","unstructured":"Simpson IJ, Marshall MR, Pilmore H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11:381\u20135.","journal-title":"Nephrology (Carlton)"},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol"},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846\u201356.","journal-title":"Cancer Immunol Res"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.ki.5002776","volume":"73","author":"E Gonz\u00e1lez","year":"2008","unstructured":"Gonz\u00e1lez E, Guti\u00e9rrez E, Galeano C, et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73:940\u20136.","journal-title":"Kidney Int"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"N Murakami","year":"2017","unstructured":"Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer. 2017;41:100\u201310.","journal-title":"Curr Probl Cancer"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0848-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T06:59:23Z","timestamp":1551250763000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0848-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0848-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"11 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report including clinical information and related images. The consent form has been stored by the corresponding author and may be obtained on request from the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"48"}}